Navigation

Skiplink Navigation

Main Features

Swiss accept third vaccine against swine flu

The Swiss Agency for Therapeutic Products, Swissmedic, has authorised a third vaccine against swine flu A/H1N1.

The product is called Celtura and is made by the Swiss pharmaceutical group, Novartis, which is based in Basel.

In a statement on Friday, the federal authorities said that unlike vaccines already authorised in October - Focetria and Pandemrix – the antigen components of Celtura were not based on hens' eggs but on a cell culture.

They said that on the basis of clinical data available, Celtura had been permitted for children above the age of three and for adults of all age groups.

But the data had shown that for adults over the age of 40, sufficient immunisation was only reached after a second vaccination of the drug. This had to be done three weeks after the first.

Swissmedic said it had not received any further applications for the authorisation of vaccines against swine flu.

swissinfo.ch and agencies


Links

Neuer Inhalt

Horizontal Line


subscription form

Form for signing up for free newsletter.

Sign up for our free newsletters and get the top stories delivered to your inbox.







Click here to see more newsletters

swissinfo EN

The following content is sourced from external partners. We cannot guarantee that it is suitable for the visually or hearing impaired.

Join us on Facebook!

×